latest update:
[TrialBase DB]

trial summary · NCT06995521

Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population

Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation

Trial record from the TrialBase DB dataset, status RECRUITING, condition GVHD, sponsored by Sung Won Choi. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06995521phase PHASE2enrollment 55start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.

Source record: https://clinicaltrials.gov/study/NCT06995521

Facts

registry idNCT06995521
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionGVHD
sponsorSung Won Choi
sponsor classOTHER
enrollment55
start date2026-12
primary completion2028-09
completion2028-09
results postednot reported

Conditions

  • GVHD

Interventions

  • Vorinostat

Countries

  • United States

Intervention types: DRUG

Work with this record